VYNE Therapeutics Offloads Its Topical Minocycline Assets To Journey Medical In $450M+ Deal

Journey Medical Corporation DERM has acquired Molecule Stabilizing Technology (MST) franchise, including Amzeeq (minocycline) topical foam and Zilxi (minocycline) topical foam from VYNE Therapeutics Inc VYNE 

  • The transaction includes cash payments of $25 million and potential milestones of up to $450 million
  • Approved by the FDA nearly 50 years ago, minocycline is a well-established molecule that has been prescribed, in oral formulation, over 30 million times in the past decade.
  • Amzeeq topical foam, 4%, is the first and only topical formulation of minocycline approved by the FDA for inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and children nine years and older. 
  • Approved by the FDA in May 2020, Zilxi topical foam, 1.5%, is the first and only topical minocycline treatment for inflammatory lesions due to rosacea in adults. 
  • Amzeeq and Zilx generated approximately $4 million in net sales in the U.S. in Q3 FY21.
  • In conjunction, Journey Medical has expanded its credit agreement with East West Bank to $30.0 million.
  • As of September 30, Journey Medical held $21.7 million as cash, cash equivalents, and restricted cash.
  • The divestiture aligns with VYNE's strategic plan. The proceeds will be used to fund the development of its immuno-inflammatory pipeline.
  • Price Action: DERM shares are down 6.49% at $5.04, and VYNE shares are up 15% at $1.15 during the premarket session on the last check Thursday.
Loading...
Loading...
DERM Logo
DERMJourney Medical Corp
$7.77-%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
96.25
Growth
Not Available
Quality
Not Available
Value
25.21
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...